RecruitingPhase 2NCT05764538

DAOIB for the Treatment of Brain Fog

DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial

Sponsor

Chang Gung Memorial Hospital

Enrollment

40 participants

Start Date

Feb 27, 2023

Study Type

INTERVENTIONAL

Conditions

Long COVID

Summary

This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DAOIB for people with long covid. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.